IBT Receives a Partnership R01 grant from NIAID to Develop a Pan-Ebolavirus Vaccine
IBT Receives a Partnership R01 grant from NIAID to Develop
IBT Receives NIH R01 grant to study the mechanisms of ebolavirus vaccine protection
IBT Receives NIH R01 grant to study the mechanisms of
IBT Receives an SBIR from NIAID for development of a post-exposure vaccine for Streptococcus pneumoniae
IBT Receives an SBIR from NIAID for development of a
Integral Molecular and Integrated BioTherapeutics Initiate Collaboration for Virus Vaccine Discovery
View the article at: http://www.businesswire.com/news/home/20170302005790/en Integral Molecular and Integrated BioTherapeutics have
International Society for Antiviral Research (ISAR) News Vol. 26 No.2
View the Article at: http://c.ymcdn.com/sites/www.isar-icar.com/resource/resmgr/docs/isar_news_avr_26_2.pdf ISAR News – Newsletter for of
IBT Announces Licensing Agreement with Emergent BioSolutions for Development of Equine Immunoglobulin Therapeutics for Filovirus Infections
Filoviruses, including Ebola, Sudan, Bundibugyo, and Marburg viruses, cause a
IBT Receives an SBIR from NIAID to engineer an Ebola Antibody to Achieve broad Filovirus Protection
A major challenge in the fight against filovirus infections is
IBT Receives an STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses
A major challenge in the fight against filovirus infections is
Progress Towards a Pan-Ebolavirus Treatment
In 2014, the alarm for the Zaire Ebola virus was
New Publication from the Researchers at IBT
Efforts to develop effective vaccines against Staphylococcus aureus (S. aureus) have been
